Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Marketing to U.S. Digital Physicians: Engaging Physicians Across Screens and Platforms
Changes in U.S. policy have accelerated the implementation and use of electronic health records (EHRs) in the practice, disrupting physician workflow and decision making. In the meanwhile, reliance…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | Decision Base | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
Prostate Cancer (First-Line – Chemotherapy-Naive – Metastatic Castrate-Resistant) | DecisionBase | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
The Impact of LATAM – Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma | Physician & Payer Forum | Brazil and Mexico | 2014
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
